Ligand Pharmaceuticals Incorporated

LGND Healthcare Biotechnology

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue
−31.8%
EPS
−123.8%
Free cash flow
−268.5%
Total debt
+153.3%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%
Market cap
$6.0B
P/E
118×
Fwd P/E
88.3×
Dividend yield
—
F-score
6/9
Altman Z
5.45
Beneish M
−4.02
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 163.60 14.24 2.41 0.00 31.61 0.00 23.79 0.00 30.01
Piotroski F-Score
5 8 7 5 5 7 4 6 5 6
P/S ratio
13.87 14.63 8.09 11.66 6.97 7.53 5.68 9.53 11.73 13.64
Altman Z-Score
2.75 4.22 2.87 4.28 2.01 3.62 5.45 10.04 11.78 5.45
P/FCF ratio
36.71 21.80 10.70 0.00 23.33 26.38 9.96 0.00 21.84 60.02
Altman Z″-Score (non-manufacturers)
(1.17) 0.26 5.22 10.46 4.19 5.61 7.17 12.55 11.45 6.75
Beneish M-Score
(1.78) (2.41) (2.08) (0.57) (1.56) (1.79) (3.98) (1.93) (3.22) (4.02)
P/Operating CF
80.74 65.94 62.42 (191.11) 2,122.44 65.80 20.83 155.09 68.83 79.63
P/B ratio
4.43 5.16 3.62 1.83 1.61 2.21 1.86 1.78 2.36 3.59
EV/Sales
14.80 14.93 7.54 8.09 7.21 7.45 5.04 8.86 10.63 12.77
EV/EBITDA
24.28 23.06 8.74 1.12 13.10 10.49 17.87 24.55 150.69 48.15
EV/FCF
39.17 22.24 9.97 (27.72) 24.13 26.11 8.84 (301.84) 19.80 56.19
Current Ratio
0.72 0.99 10.58 66.09 5.00 11.15 2.67 14.15 8.93 22.23
Net Debt/EBITDA
1.53 0.46 (0.63) (0.49) 0.43 (0.11) (2.26) (3.59) (22.58) (4.36)
Debt/Equity
0.71 0.61 1.13 0.83 0.63 0.39 0.15 0.00 0.00 0.44
ROE
(0.57%) 3.39% 29.84% 94.76% (0.40%) 7.47% (4.70%) 8.03% (0.53%) 13.47%
ROA
(0.30%) 1.97% 14.84% 45.67% (0.21%) 4.30% (3.24%) 6.73% (0.47%) 9.95%
ROIC
6.20% 9.64% 24.17% 149.54% 3.13% 8.10% 0.40% 1.41% (2.50%) 3.62%
Return on Tangible Assets
2.63% 530.91% 18.06% 56.50% (0.72%) 13.10% (18.82%) 22.08% (1.30%) 15.66%
Average Days of Receivables
49.24 66.21 81.28 126.69 131.81 138.49 65.17 109.27 92.70 83.12
Earnings Yield
(0.08%) 0.61% 7.02% 41.45% (0.20%) 3.16% (3.00%) 4.20% (0.05%) 3.33%
Free Cash Flow Yield
2.72% 4.59% 9.35% (2.50%) 4.29% 3.79% 10.04% (0.31%) 4.58% 1.67%
Free Cash Flow per Share
1.98 4.44 8.66 (1.68) 3.18 4.24 7.12 (0.22) 4.64 2.50
Book value per Share
16.38 19.01 26.51 40.39 43.84 49.38 35.42 40.52 45.40 52.60
Free Cash Flow
41.19 93.47 183.17 (31.89) 51.49 70.53 120.02 (3.85) 84.84 48.31
EV/EBIT
36.76 30.94 11.58 1.21 31.44 17.34 325.52 97.41 0.00 83.48
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026